FORMA Therapeutics Grants Genentech Exclusive Rights to Acquire a Pre-clinical Cancer Program
News Jul 14, 2011
Under the terms of the agreement, the parties will enter into a research collaboration, following which, Genentech will be responsible for all development activities and will have the option to acquire the entire program from FORMA at a defined future phase of development. FORMA will receive an undisclosed upfront payment, research funding, and is eligible to receive milestone payments upon the successful achievement of certain development milestones. If Genentech subsequently acquires the program, FORMA will receive a significant buy-out payment and will be eligible for additional milestone payments if certain sales thresholds are met.
James Sabry, Vice President of Genentech Partnering, said "Genentech is very pleased to enter into this structurally innovative agreement with FORMA. The program represents a promising addition to our portfolio and we are hopeful it has the potential to make a meaningful difference in the lives of cancer patients."
“This agreement with Genentech is the culmination of exceptional hard work from our scientists which identified many exciting molecules and potential clinical candidates against this important target in less than 18 months,” said Ken Bair, Head of R&D of FORMA. “This agreement provides FORMA with significant near-term financial resources to accelerate the additional internal drug discovery programs ongoing at FORMA targeting essential cancer targets in the areas such as cancer metabolism and protein-protein interactions. The potential program buy-out payment and milestones could potentially yield an attractive return for FORMA’s investors.” added Steven Tregay, CEO of FORMA.
A team of researchers has discovered a combination of pharmaceutical drugs that not only increases healthy lifespan in the microscopic worm Caenorhabditis elegans (C. elegans), but also delays the rate of ageing in them, a finding that could someday mean longer, healthier lives for humans.READ MORE
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019